患者来源富含pIgR的细胞外囊泡驱动肝细胞癌的干性、肿瘤发生与转移
本研究探讨患者来源的细胞外囊泡(EVs)在肝细胞癌(HCC)中对肿瘤干性和肿瘤发生的调控作用。晚期HCC患者循环EVs中pIgR表达显著升高,EV-pIgR通过激活PDK1/Akt/GSK3β/β-catenin信号轴促进肿瘤干性和侵袭性,抗pIgR中和抗体可减弱小鼠肿瘤生长。
要点
- 晚期HCC患者循环EVs的pIgR表达较对照个体显著升高。
- EV-pIgR通过激活PDK1/Akt/GSK3β/β-catenin信号轴促进肿瘤干性与侵袭。
- 抗pIgR中和抗体可减弱PDTX小鼠模型中的肿瘤生长。
核心结论
- EV-pIgR通过激活PDK1/Akt/GSK3β/β-catenin信号级联调控肿瘤干性与侵袭性。
- 阻断肿瘤微环境中EV-pIgR介导的细胞间通讯可能为癌症患者提供新的治疗策略。
研究设计与样本
- 从患者血清中分离、定量并表征EVs,通过体外和体内功能实验进行验证。
- 采用蛋白质组学分析鉴定EVs功能组分,通过ELISA、免疫印迹、免疫组化和定量PCR检测pIgR。
- 在植入患者来源肿瘤异种移植(PDTX)的裸鼠中使用中和抗体阻断EV-pIgR。
主要发现
- 晚期HCC患者循环EVs的pIgR表达较对照个体显著升高。
- 抗pIgR抗体阻碍晚期HCC-EVs对肿瘤干性和肿瘤发生的增强作用。
- 富含pIgR的EVs促进受体细胞的肿瘤干性和癌性表型。
- Akt和β-catenin抑制剂消除EV-pIgR诱导的癌症侵袭性,证实其依赖PDK1/Akt/GSK3β/β-catenin信号轴激活。
- 抗pIgR中和抗体减弱PDTX小鼠的肿瘤生长。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Extracellular vesicles (EVs) play a pivotal role in connecting tumor cells with their local and distant microenvironments. Herein, we aimed to understand the role (on a molecular basis) patient-derived EVs play in modulating cancer stemness and tumorigenesis in the context of hepatocellular carcinoma (HCC). METHODS: EVs from patient sera were isolated, quantified and characterized. The EVs were vigorously tested, both in vitro and in vivo, through various functional assays. Proteomic analysis was performed to identify the functional components of EVs. The presence and level of polymeric immunoglobulin receptor (pIgR) in circulating EVs and tumor and non-tumorous tissues of patients with HCC were determined by ELISA, immunoblotting, immunohistochemistry and quantitative PCR. The functional role and underlying mechanism of EVs with enhanced pIgR expression were elucidated. Blockade of EV-pIgR with neutralizing antibody was performed in nude mice implanted with patient-derived tumor xenografts (PDTXs). RESULTS: Circulating EVs from patients with late-stage HCC (L-HCC) had significantly elevated pIgR expression compared to the EVs released by control individuals. The augmenting effect of L-HCC-EVs on cancer stemness and tumorigenesis was hindered by an anti-pIgR antibody. EVs enriched with pIgR consistently promoted cancer stemness and cancerous phenotypes in recipient cells. Mechanistically, EV-pIgR-induced cancer aggressiveness was abrogated by Akt and β-catenin inhibitors, confirming that the role of EV-pIgR depends on the activation of the PDK1/Akt/GSK3β/β-catenin signaling axis. Furthermore, an anti-pIgR neutralizing antibody attenuated tumor growth in mice implanted with PDTXs. CONCLUSIONS: This study illustrates a previously unknown role of EV-pIgR in regulating cancer stemness and aggressiveness: EV-pIgR activates PDK1/Akt/GSK3β/β-catenin signaling cascades. The blockade of the intercellular communication mediated by EV-pIgR in the tumor microenvironment may provide a new therapeutic strategy for patients with cancer. LAY SUMMARY: The World Health Organization estimates that more than 1 million patients will die from liver cancer, mostly hepatocellular carcinoma (HCC), in 2030. Understanding the underlying mechanism by which HCC acquires aggressive attributes is crucial to improving the diagnosis and treatment of patients. Herein, we demonstrated that nanometer-sized extracellular vesicles released by tumors promote cancer stemness and tumorigenesis. Within these oncogenic vesicles, we identified a key component that functions as a potent modulator of cancer aggressiveness. By inhibiting this functional component of EVs using a neutralizing antibody, tumor growth was profoundly attenuated in mice. This hints at a potentially effective therapeutic alternative for patients with cancer.
引用
- Tey SK, Wong SWK, Chan JYT, et al. Patient pIgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. J Hepatol. 2021. PMID: 34922977. doi:10.1016/j.jhep.2021.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。